导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.88% | 1493/4773 |
| 近一周 | -2.09% | 1201/5462 |
| 近一月 | -1.32% | 912/5421 |
| 近一季 | -1.43% | 996/5209 |
| 近半年 | -6.64% | 3118/4920 |
| 近一年 | 9.08% | 1126/4366 |
| 近两年 | 45.33% | 1630/2954 |
| 近三年 | 38.88% | 747/2253 |
| 成立以来 | 178.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.37% 530/4961 |
-5.65% 3604/5312 |
- - |
- - |
| 2025 | 16.70% 2422/4813 |
-1.82% 2787/3635 |
0.02% 2774/4076 |
13.91% 2960/4524 |
4.33% 541/4813 |
| 2024 | 17.17% 721/3463 |
7.93% 212/2808 |
0.65% 562/3014 |
8.78% 2725/3129 |
-0.85% 1530/3463 |
| 2023 | 9.23% 116/2656 |
6.77% 648/2280 |
1.86% 194/2385 |
2.01% 262/2515 |
-1.55% 341/2655 |
| 2022 | -9.76% 186/2207 |
-0.41% 126/1919 |
-1.51% 1734/2016 |
-9.10% 244/2113 |
1.21% 1344/2208 |
| 2021 | 24.93% 116/1822 |
8.56% 62/1255 |
2.75% 990/1330 |
7.20% 193/1466 |
4.47% 330/1822 |
| 2020 | 25.18% 621/1250 |
-5.31% 408/1028 |
11.09% 747/1067 |
15.85% 191/1164 |
2.72% 971/1184 |
| 2019 | 20.40% 666/1092 |
20.32% 612/739 |
-4.84% 434/788 |
-0.13% 579/850 |
5.29% 732/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 富国中证价值ETF联接A VS. 长安沪深300非周期A(740101) |